C4 Therapeutics Inc
NASDAQ:CCCC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.18
11
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
C4 Therapeutics Inc
Pre-Tax Income
C4 Therapeutics Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
C4 Therapeutics Inc
NASDAQ:CCCC
|
Pre-Tax Income
-$131.2m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$7.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
19%
|
CAGR 10-Years
4%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$176m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-34%
|
||
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-1%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$259.6m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
C4 Therapeutics Inc
Glance View
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
See Also
What is C4 Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-131.2m
USD
Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Pre-Tax Income amounts to -131.2m USD.
What is C4 Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-53%
Over the last year, the Pre-Tax Income growth was -2%. The average annual Pre-Tax Income growth rates for C4 Therapeutics Inc have been -25% over the past three years , -53% over the past five years .